Acne

| Lesion | Description |
|---|---|
| Closed comedone (whitehead) | 1–2 mm pebbly white papule; follicular orifice blocked; precursor to inflammatory lesions |
| Open comedone (blackhead) | Dilated follicular orifice filled with oxidized, darkened sebum; rarely inflammatory |
| Papule | Small inflammatory lesion |
| Pustule | Inflammatory lesion containing pus |
| Nodule/cyst | Large inflammatory lesions; may drain and cause scarring |
| Agent | Mechanism | Notes |
|---|---|---|
| Retinoids (tretinoin, adapalene, tazarotene, trifarotene) | Normalize follicular epithelium differentiation; loosen microcomedones; anti-inflammatory | Apply to entire acne-prone area once daily; tretinoin in the evening (UV inactivation); benefit not evident for 6–8 weeks; apparent flare in first month is expected |
| Benzoyl peroxide | Bactericidal against C. acnes; reduces free fatty acids | Reduces risk of antibiotic resistance; used with retinoids and antibiotics |
| Topical antibiotics (clindamycin, erythromycin) | Anti-inflammatory; suppresses C. acnes | Used with benzoyl peroxide to limit resistance |
| Topical dapsone | Anti-inflammatory | Particularly useful in adult female acne |
| Agent | Use Case |
|---|---|
| Oral antibiotics (doxycycline, minocycline, sarecycline) | Moderate–severe inflammatory acne; reduce C. acnes and inflammation |
| Oral contraceptives (combined estrogen-progestin) | Hormonal acne in females; reduces androgen-driven sebum production |
| Spironolactone | Anti-androgen; adult female acne |
| Isotretinoin (oral) | Severe nodular/cystic acne; scarring acne unresponsive to other therapies; reduces sebum production profoundly; teratogenic — requires iPLEDGE program in the US |